Evofosfamide


Cat. No.:	HY-10535			
CAS No.:	918633-87-1			
Molecular Formula:	$C_9H_{16}Br_2N_5O_4P$			
Molecular Weight:	449.04			
Target:	Apoptosis			
Pathway:	Apoptosis			
Storage:	Powder	-20°C	3 years	
		4°C	2 years	
	In solvent	-80°C	6 months	
		-20°C	1 month	

SOLVENT & SOLUBILITY

H ₂ O : 4.35 mg Preparing Stock Solutio	DMSO : 94 mg/mL (209.34 mM; Need ultrasonic and warming) H ₂ O : 4.35 mg/mL (9.69 mM; ultrasonic and warming and heat to 60°C)						
		Solvent Mass Concentration	1 mg	5 mg	10 mg		
	Preparing Stock Solutions	1 mM	2.2270 mL	11.1349 mL	22.2697 mL		
		5 mM	0.4454 mL	2.2270 mL	4.4539 mL		
		10 mM	0.2227 mL	1.1135 mL	2.2270 mL		
	Please refer to the so	Please refer to the solubility information to select the appropriate solvent.					
n Vivo		1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.57 mM); Clear solution					
		2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.57 mM); Clear solution					
		3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.57 mM); Clear solution					

BIOLOGICAL ACTIVITY				
Description	Evofosfamide (TH-302) is a hypoxia-activated proagent with IC ₅₀ of 10 μM and 1000 μM in hypoxia (N ₂) and normoxia (21% O ₂), respectively.			
IC ₅₀ & Target	Hypoxia-activated prodrug ^[1]			
In Vitro	Evofosfamide (TH-302) induces γH2AX and apoptosis. Evofosfamide displays hypoxia-selective and concentration-			





Product Data Sheet

dependent cytotoxic activity that is comparable in both p53-proficient and -deficient cells. Treatment with Evofosfamide (TH-302) alone causes an accumulation of G_2/M cells. Inhibition of Chk1 by PF47736 in cells treated with Evofosfamide reduces Evofosfamide (TH-302)-mediated G_2/M arrest under both normoxia and hypoxia^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo Evofosfamide (TH-302) is a hypoxia-activated prodrug known to activate selectively under the hypoxic conditions commonly found in solid tumors. The mean values of normalized K^{trans} decrease 69.2% for Evofosfamide (TH-302)-treated mice in Hs766t tumors, decrease 46.1% for Mia PaCa-2 tumors and increase 4.9% in SU.86.86 tumors. Both changes for Hs766t and Mia PaCa-2 treatment groups are statistically significant (P<0.01) when compare to their own control group^[2]. A significant reduction in the hypoxic fraction (HF) to 2.1%±4.7% is seen after 95% oxygen breathing (P<0.001), whereas 7% oxygen breathing significantly increase the HF to 29.5%±14.7% (P=0.029). Exposing rhabdomyosarcoma-bearing rats to increasing oxygen conditions abolish the effect of TH-302 and reduce the T4×SV from 20.4±3.5 to 15.3±2.5 days (P=0.007), whereas control animals have an increased T4×SV. Upon combination with radiotherapy, the T4×SV of TH-302-treated tumors decrease from 30.8±5.9 (Evofosfamide (TH-302)+radiotherapy) to 25.7±2.9 days (Evofosfamide (TH-302)+radiotherapy+95% O₂)^[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL	
Cell Assay ^[1]	Cells are treated with 0.1 μM of either PF477736 or AZD7762 and Evofosfamide (TH-302) for 2 h under either normoxia (21% O ₂) or hypoxia (N ₂). Following wash, cells are cultured for additional 22 h in the presence of Chk1 inhibitor under normoxia. Cells are fixed in 75% ethanol and cell cycle distribution is determined using cell cycle reagent and Guava flow cytometry. HT-29 cells are exposed to Evofosfamide (TH-302)e (8 nM, 40 nM, 200 nM, 1 μM, and 5 μM) and 0.1 μM of AZD7762 for 2 h under either normoxia (21% O ₂) or hypoxia (N ₂). After wash, cells are continuously cultured for additional 46 h in the presence of 0.1 μM of AZD7762. Luminescence-based caspase activity assay is performed ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^{[2][3]}	Mice ^[2] Female SCID mice of age 5-6 weeks are inoculated with SU.86.86, Hs766t or Mia-PaCa2 cells (5×10 ⁶) subcutaneously on the left hind leg. Tumors are allowed to grow for an average of three weeks to an average size of ~150 mm ³ . Mice are then randomized and placed into cohorts and treated with saline (control) or Evofosfamide (TH-302) (50 mg/kg) injected intraperitoneally. A total of 34 mice underwent MR imaging studies. The SU.86.86 group consist of 5 TH-302 treated and 5 control animals; Mia-PaCa2 consist of 6 Evofosfamide treated and 5 control animals; Hs766t consist of 7 Evofosfamide treated and 6 control animals. Animals are sacrificed when tumors reach 2000 mm ³ . Rats ^[2] Syngeneic rhabdomyosarcoma R1 tumors (1 mm ³) are implanted subcutaneously in the lateral flank of adult WAG/Rij rats. Experiments are started upon a mean tumor volume of 4.2 cm ³ (range, 2.0-8.1) to ensure a stable HF. Treatment is administered on 4 consecutive days and consist of an intraperitoneal injection (i.p.; QD×4) with either NaCl or Evofosfamide (TH-302) (25, 50, or 75 mg/kg). Before the start of treatment, a PET scan is made using [¹⁸ F]HX4. Radiotherapy is applied in a single dose of 0, 4, 8, or 12 Gy on day 3 of the treatment, 3 hours after NaCl or Evofosfamide (TH-302) injection, 1 hour after oxygen modification. During both PET imaging and radiotherapy, rats are anesthetized using a mixture of ketamine/xylazine (i.p.; 66.7 and 6.7 mg/kg, respectively). During the 5 days of treatment (1 day PET imaging, 4 days of injections with Evofosfamide or vehicle), animals are exposed to modified oxygen concentrations for 4 hours per day in order to alter the HF of the tumor. The combination oxygen modification of nicotinamide (i.p. 500 mg/kg) and carbogen (95% oxygen, 5% CO ₂ ; 5 L/minute) consist of a nicotinamide injection and 30 minutes later the exposure to carbogen breathing for 3.5 hours. In the middle of the nicotinamide/carbogen treatment, NaCL/Evofosfamide injection after the first 2 hours. The injection of the

CUSTOMER VALIDATION

- Front Oncol. 30 April 2021.
- ACS Med Chem Lett. 2015 Jun 22;6(8):948-52.
- SLAS Discov. 2023 Dec 13:S2472-5552(23)00092-8.
- SLAS Discov. 25 October 2021.

See more customer validations on <u>www.MedChemExpress.com</u>

REFERENCES

[1]. Meng F, et al. Enhancement of hypoxia-activated prodrug TH-302 anti-tumor activity by Chk1 inhibition. BMC Cancer. 2015 May 21;15:422.

[2]. Zhang X, et al. MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer Xenografts. PLoS One. 2016 May 26;11(5):e0155289.

[3]. Peeters SG, et al. TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [¹⁸F]HX4 Hypoxia PET Imaging. Clin Cancer Res. 2015 Jul 1;21(13):2984-92.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA